CanSino Biologics (SHA:688185, HKG:6185) obtained acceptance from China's medical products administrator for its drug registration and marketing authorization application for its adsorbed acellular pertussis, diphtheria and tetanus combined vaccine.
The vaccine is intended for persons aged six years and above, according to a Monday filing with the Shanghai bourse.
Shares of the vaccine manufacturer closed 3% higher Monday.